CYP450酶特性及其应用研究进展

中国临床药理学与治疗学 ›› 2008, Vol. 13 ›› Issue (8): 942-946.

CYP450酶特性及其应用研究进展

李晓宇, 刘皋林

上海交通大学附属第一人民医院临床药学室, 上海200080

收稿日期:2008-06-11 修回日期:2008-07-16 出版日期:2008-08-26 发布日期:2020-10-12
通讯作者: 刘皋林, 男, 博士, 教授, 博士生导师, 研究方向:免疫抑制剂分子干预机制及临床药理学。Tel:021-63240090-4038　E-mail:gaolinliu@yahoo.com.cn
作者简介:李晓宇, 男, 博士, 讲师, 研究方向:药代动力学与临床药理学。Tel:021-63240090-4030　E-mail:xyllxb@yahoo.com.cn
基金资助:
中国博士后科学基金资助(20080430662);上海市博士后科研基金资助(08R214138)

Research advance on the characteristics and application of CYP450 metabolic enzymes

LI Xiao-yu, LIU Gao-lin

Department of Clinical Pharmacy, Affiliated First People's Hospital of Shanghai Jiaotong University, Shanghai 200080, China

Received:2008-06-11 Revised:2008-07-16 Online:2008-08-26 Published:2020-10-12

摘要/Abstract

摘要： 细胞色素P450(CYP450)是药物和其他内、外源物的主要代谢酶, 本文综述了人体内参与药物代谢的几种主要代谢酶CYP3A4、CYP2D6、CYP2C9、CYP2C19、CYP2E1、CYP1A2和CYP2A6的分子生物学特征, 中药对药物代谢酶的影响及药物代谢酶在临床药物治疗和新药研究过程中的应用。

关键词: 药物代谢酶, 细胞色素P450, 药物治疗, 新药研究

Abstract: Cytochrome P450 is an important kind of enzymes for the metabolism of drug and other endoor xeno-biotics.Classification of metabolic enzymes, molecular biological characteristic of CYP3A4, CYP2D6, CYP2C9, CYP2C19, CYP2E1, CYP1A2 and CYP2A6were described in this review.Influence of traditional Chinese medicine (TCM)on metabolic enzyme and its application in clinical drug therapeutics and drug development were also reviewed in this article.

Key words: drug metabolic enzyme, cytochrome P450, drug treatment, new drug investigation

中图分类号:

R968

李晓宇, 刘皋林. CYP450酶特性及其应用研究进展[J]. 中国临床药理学与治疗学, 2008, 13(8): 942-946.

LI Xiao-yu, LIU Gao-lin. Research advance on the characteristics and application of CYP450 metabolic enzymes[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2008, 13(8): 942-946.

参考文献 22

[1]	成碟, 徐为人, 刘昌孝.细胞色素P450(CYP450)遗传多态性研究进展[J].中国药理学通报, 2006, 22(12):1409-1414.
[2]	Park BK.Cytochrome P450enzymes in the heart[J]. Lancet, 2000, 355(9208):945.
[3]	易飞, 周宏灏.天然药物对CYP3A 的影响[J].中国临床药理学与治疗学, 2008, 13(3):344-349.
[4]	程春雷, 游雪甫.细胞色素P4503A 研究进展[J]. 国外医药抗生素分册, 2004, 25(3):124-128.
[5]	Gonzalez FJ, Meyer UA.Molecular genetics of the debrisoquine sparteine polymorphism [J].Clin Pharmacol Ther, 1991, 50(3):233-238.
[6]	Ingelman-Sundberg M, Sim SC, Gomez A, et al.Influence of cytochrome P450 polymorphisms on drug therapies :pharmacogenetic, pharmacoepigenetic and clinical aspects[J].Pharmacol Ther, 2007, 116(3):496-526.
[7]	Van Schaik RH.CYP450 pharmacigenetics for personalizing cancer therapy [J].Drug Resist Updat, 2008, 11(3):77-98.
[8]	卢爱华, 舒焱, 周宏灏.细胞色素氧化酶CYP2C9的中国临床药理学与治疗学 2008 Aug;13(8)· 945· 研究进展[J].中国临床药理学杂志, 2000, 6(5):381-385.
[9]	陈马昆, 王睿.药物代谢酶细胞色素P4502C9研究进展[J].中国临床药理学与治疗学, 2004, 9(6):601-606.
[10]	Yasar U, Tybring a.Role of CYP2C9polymorphism in losartan oxidation[J].Drug Metab Dispos, 2001, 29(7): 1051-1056.
[11]	Ingelman SM.Pharmacogenetics of cytochrome P450 and its applications in drug therapy :the past, present and future[J].Trends Pharmacol ScI, 2004, 25(4):193-200.
[12]	赵伟红, 陈枢青.细胞色素P4502C19基因多态性的研究进展[J].宁波大学学报:理工版, 2004, 17(2): 230-233.
[13]	Umeno M, Mcbride OW, Yang CS, et al.Human ethanol-inducible P4502E1:complete gene sequence promoter characterization, chromosome mapping, and cDNA directed expression[J].Biochemistry, 1988, 27(25):9006-9013.
[14]	伍忠銮, 谢红光, 周宏灏.细胞色素P4502E1的研究进展[J].中国临床药理学杂志, 1997, 13(1):57-62.
[15]	Mikhailova ON, Gulyaeva LF, Filipenko ML, et al.Enhancer elements in mouse CYP1A2 gene :Acomparative sequencing among different inbred mouse strains[J].Genetic Toxicol EnvironMutagen, 2007, 632:99-103.
[16]	Sellers EM, Tyndale RF, Fernanddes LC.Decreasing smoking behaviour and risk through CYP2A6inhibition [J].Drug Discov Today, 2003, 8(11):487-493.
[17]	Fuhr U.Induction of drug metabolizing enzymes :pharmacokinetic and toxicological consequences in humans[J]. Clin Pharmacokinet, 2000, 38(6):493-504.
[18]	CaIWM.Advance prospect of pharmacogenetics on the personalized medicine[J].Chin Pharm J, 2003, 38(8): 572-575.
[19]	Adrine FB.Herb-drug interactions[J].Lancet, 2000, 355:134-138.
[20]	高晓新, 梁爱华, 郑素勤.中草药对细胞色素P450酶系影响的研究进展[J].中国实验方剂学杂志, 2006, 12(9):65-67.
[21]	Jensen CB, Jollow DJ.The role of N-hydroxyphenetidine in phenacetin-induced hemolytic anemia[J].Toxicol Appl Pharmacol, 1991, 111(1):212.
[22]	Wilkinson GR.Cytochrome P4503A (CYP3A)metabolism :prediction of invitor activity in humans[J].J Pharmacokinet Biopharm, 1996, 24(5):475-490.